Abstract
Historically the therapeutic potential of polyclonal passive immunotherapies in viral diseases has been related to antiviral neutralizing antibodies, but there is also considerable evidence that non-neutralizing antibodies can translate into clinical benefit as well. In the setting of SARS-CoV-2 infection, we review here in vitro and in vivo evidence supporting a contributing role for anti-nucleocapsid antibodies. Retrospective investigation of anti-nucleocapsid antibody levels in randomized clinical trials of COVID-19 convalescent plasma is warranted to better understand whether there is an association with efficacy or lack thereof.
Subject
Virology,Infectious Diseases
Reference48 articles.
1. Viral infection neutralization tests: A focus on SARS-CoV-2 with implications for convalescent plasma therapy;Focosi;Rev. Med Virol.,2020
2. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection;Khoury;Nat. Med.,2021
3. Natarajan, H., Crowley, A.R., Butler, S.E., Xu, S., Weiner, J.A., Bloch, E.M., Littlefield, K., Wieland-Alter, W., Connor, R.I., Wright, P.F., Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma. mBio, 2021. 12.
4. Convalescent Plasma Antibody Levels and the Risk of Death from COVID-19;Joyner;N. Engl. J. Med.,2021
5. Early High-Titer Plasma Therapy to Prevent Severe COVID-19 in Older Adults;Libster;N. Engl. J. Med.,2021
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献